{"denoms":[{"counts":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"10"},{"groupId":"BG005","value":"11"},{"groupId":"BG006","value":"3"},{"groupId":"BG007","value":"3"},{"groupId":"BG008","value":"3"},{"groupId":"BG009","value":"6"},{"groupId":"BG010","value":"3"},{"groupId":"BG011","value":"22"},{"groupId":"BG012","value":"16"},{"groupId":"BG013","value":"25"},{"groupId":"BG014","value":"25"},{"groupId":"BG015","value":"44"},{"groupId":"BG016","value":"25"},{"groupId":"BG017","value":"55"},{"groupId":"BG018","value":"21"},{"groupId":"BG019","value":"26"},{"groupId":"BG020","value":"306"}],"units":"Participants"}],"groups":[{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 0.3 mg/kg 1Q3W until the end of treatment.","id":"BG000","title":"Dose-escalation Part: Enapotamab Vedotin 0.3 mg/kg 1Q3W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 0.6 mg/kg 1Q3W until the end of treatment.","id":"BG001","title":"Dose-escalation Part: Enapotamab Vedotin 0.6 mg/kg 1Q3W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 1.0 mg/kg 1Q3W until the end of treatment.","id":"BG002","title":"Dose-escalation Part: Enapotamab Vedotin 1.0 mg/kg 1Q3W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 1.5 mg/kg 1Q3W until the end of treatment.","id":"BG003","title":"Dose-escalation Part: Enapotamab Vedotin 1.5 mg/kg 1Q3W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 2.0 mg/kg 1Q3W until the end of treatment.","id":"BG004","title":"Dose-escalation Part: Enapotamab Vedotin 2.0 mg/kg 1Q3W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 2.2 mg/kg 1Q3W until the end of treatment.","id":"BG005","title":"Dose-escalation Part: Enapotamab Vedotin 2.2 mg/kg 1Q3W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 2.4 mg/kg 1Q3W until the end of treatment.","id":"BG006","title":"Dose-escalation Part: Enapotamab Vedotin 2.4 mg/kg 1Q3W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 0.6 mg/kg 3Q4W until the end of treatment.","id":"BG007","title":"Dose-escalation Part: Enapotamab Vedotin 0.6 mg/kg 3Q4W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 0.8 mg/kg 3Q4W until the end of treatment.","id":"BG008","title":"Dose-escalation Part: Enapotamab Vedotin 0.8 mg/kg 3Q4W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 1.0 mg/kg 3Q4W until the end of treatment.","id":"BG009","title":"Dose-escalation Part: Enapotamab Vedotin 1.0 mg/kg 3Q4W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 1.2 mg/kg 3Q4W until the end of treatment.","id":"BG010","title":"Dose-escalation Part: Enapotamab Vedotin 1.2 mg/kg 3Q4W"},{"description":"Participants with advanced and/or classical metastatic NSCLC with classical sensitizing EGFR mutations and/or EGFR mutations targeted by third-generation tyrosine kinase inhibitors) received IV infusion of enapotamab vedotin 2.2 mg/kg 1Q3W until the end of treatment.","id":"BG011","title":"Expansion Part Cohort 1: Enapotamab Vedotin 2.2 mg/kg 1Q3W"},{"description":"Participants with advanced and/or metastatic melanoma with BRAF V600 mutation received IV infusion of enapotamab vedotin 2.2 mg/kg 1Q3W until the end of treatment.","id":"BG012","title":"Expansion Part Cohort 3: Enapotamab Vedotin 2.2 mg/kg 1Q3W"},{"description":"Participants with advanced and/or metastatic melanoma with BRAF V600 wild type received IV infusion of enapotamab vedotin 2.2 mg/kg 1Q3W until the end of treatment.","id":"BG013","title":"Expansion Part Cohort 4: Enapotamab Vedotin 2.2 mg/kg 1Q3W"},{"description":"Participants with advanced and/or metastatic sarcoma received IV infusion of enapotamab vedotin 2.2 mg/kg 1Q3W until the end of treatment.","id":"BG014","title":"Expansion Part Cohort 5: Enapotamab Vedotin 2.2 mg/kg 1Q3W"},{"description":"Participants with advanced and/or metastatic solid tumors (excluding NSCLC, melanoma, sarcoma, and ovarian cancer unless having a known AXL gene amplification) received IV infusion of enapotamab vedotin 1.0 mg/kg 3Q4W until the end of treatment.","id":"BG015","title":"Expansion Part Cohort 6: Enapotamab Vedotin 1.0 mg/kg 3Q4W"},{"description":"Participants with advanced and/or metastatic platinum-resistant ovarian cancer received IV infusion of enapotamab vedotin 2.2 mg/kg 1Q3W until the end of treatment.","id":"BG016","title":"Expansion Part Cohort 7: Enapotamab Vedotin 2.2 mg/kg 1Q3W"},{"description":"Participants with advanced and/or metastatic NSCLC without activating EGFR mutations or ALK rearrangements received IV infusion of enapotamab vedotin 2.2 mg/kg 1Q3W until the end of treatment.","id":"BG017","title":"Expansion Part Cohort 2: Enapotamab Vedotin 2.2 mg/kg 1Q3W"},{"description":"Participants with advanced and/or metastatic NSCLC without activating EGFR mutations or ALK rearrangements received IV infusion of enapotamab vedotin 1.8 mg/kg 1Q3W until the end of treatment.","id":"BG018","title":"Expansion Part Cohort 2: Enapotamab Vedotin 1.8 mg/kg 1Q3W"},{"description":"Participants with advanced and/or metastatic NSCLC without activating EGFR mutations or ALK rearrangements received IV infusion of enapotamab vedotin 1.0 mg/kg 3Q4W until the end of treatment.","id":"BG019","title":"Expansion Part Cohort 8: Enapotamab Vedotin 1.0 mg/kg 3Q4W"},{"description":"Total of all reporting groups","id":"BG020","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"9"},{"groupId":"BG005","value":"5"},{"groupId":"BG006","value":"2"},{"groupId":"BG007","value":"1"},{"groupId":"BG008","value":"2"},{"groupId":"BG009","value":"4"},{"groupId":"BG010","value":"3"},{"groupId":"BG011","value":"12"},{"groupId":"BG012","value":"14"},{"groupId":"BG013","value":"13"},{"groupId":"BG014","value":"15"},{"groupId":"BG015","value":"23"},{"groupId":"BG016","value":"16"},{"groupId":"BG017","value":"24"},{"groupId":"BG018","value":"15"},{"groupId":"BG019","value":"17"},{"groupId":"BG020","value":"180"}]}],"title":">=18 to <65 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"6"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"2"},{"groupId":"BG008","value":"1"},{"groupId":"BG009","value":"2"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"10"},{"groupId":"BG012","value":"2"},{"groupId":"BG013","value":"12"},{"groupId":"BG014","value":"10"},{"groupId":"BG015","value":"21"},{"groupId":"BG016","value":"9"},{"groupId":"BG017","value":"31"},{"groupId":"BG018","value":"6"},{"groupId":"BG019","value":"9"},{"groupId":"BG020","value":"126"}]}],"title":">=65 years"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"7"},{"groupId":"BG005","value":"10"},{"groupId":"BG006","value":"3"},{"groupId":"BG007","value":"2"},{"groupId":"BG008","value":"2"},{"groupId":"BG009","value":"6"},{"groupId":"BG010","value":"3"},{"groupId":"BG011","value":"13"},{"groupId":"BG012","value":"8"},{"groupId":"BG013","value":"7"},{"groupId":"BG014","value":"14"},{"groupId":"BG015","value":"17"},{"groupId":"BG016","value":"25"},{"groupId":"BG017","value":"25"},{"groupId":"BG018","value":"11"},{"groupId":"BG019","value":"13"},{"groupId":"BG020","value":"174"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"1"},{"groupId":"BG008","value":"1"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"9"},{"groupId":"BG012","value":"8"},{"groupId":"BG013","value":"18"},{"groupId":"BG014","value":"11"},{"groupId":"BG015","value":"27"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"30"},{"groupId":"BG018","value":"10"},{"groupId":"BG019","value":"13"},{"groupId":"BG020","value":"132"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"1"},{"groupId":"BG014","value":"1"},{"groupId":"BG015","value":"1"},{"groupId":"BG016","value":"1"},{"groupId":"BG017","value":"1"},{"groupId":"BG018","value":"0"},{"groupId":"BG019","value":"0"},{"groupId":"BG020","value":"6"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"10"},{"groupId":"BG005","value":"11"},{"groupId":"BG006","value":"2"},{"groupId":"BG007","value":"3"},{"groupId":"BG008","value":"3"},{"groupId":"BG009","value":"6"},{"groupId":"BG010","value":"3"},{"groupId":"BG011","value":"22"},{"groupId":"BG012","value":"16"},{"groupId":"BG013","value":"24"},{"groupId":"BG014","value":"24"},{"groupId":"BG015","value":"43"},{"groupId":"BG016","value":"23"},{"groupId":"BG017","value":"53"},{"groupId":"BG018","value":"21"},{"groupId":"BG019","value":"25"},{"groupId":"BG020","value":"297"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"0"},{"groupId":"BG016","value":"1"},{"groupId":"BG017","value":"1"},{"groupId":"BG018","value":"0"},{"groupId":"BG019","value":"1"},{"groupId":"BG020","value":"3"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"0"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"1"},{"groupId":"BG018","value":"0"},{"groupId":"BG019","value":"0"},{"groupId":"BG020","value":"1"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"1"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"3"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"1"},{"groupId":"BG015","value":"2"},{"groupId":"BG016","value":"1"},{"groupId":"BG017","value":"1"},{"groupId":"BG018","value":"1"},{"groupId":"BG019","value":"1"},{"groupId":"BG020","value":"11"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"1"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"0"},{"groupId":"BG018","value":"0"},{"groupId":"BG019","value":"0"},{"groupId":"BG020","value":"1"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"3"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"3"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"0"},{"groupId":"BG018","value":"0"},{"groupId":"BG019","value":"0"},{"groupId":"BG020","value":"7"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"10"},{"groupId":"BG005","value":"10"},{"groupId":"BG006","value":"2"},{"groupId":"BG007","value":"3"},{"groupId":"BG008","value":"2"},{"groupId":"BG009","value":"6"},{"groupId":"BG010","value":"3"},{"groupId":"BG011","value":"18"},{"groupId":"BG012","value":"12"},{"groupId":"BG013","value":"21"},{"groupId":"BG014","value":"24"},{"groupId":"BG015","value":"37"},{"groupId":"BG016","value":"20"},{"groupId":"BG017","value":"50"},{"groupId":"BG018","value":"20"},{"groupId":"BG019","value":"23"},{"groupId":"BG020","value":"269"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"0"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"0"},{"groupId":"BG018","value":"0"},{"groupId":"BG019","value":"0"},{"groupId":"BG020","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"1"},{"groupId":"BG012","value":"4"},{"groupId":"BG013","value":"1"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"1"},{"groupId":"BG016","value":"4"},{"groupId":"BG017","value":"3"},{"groupId":"BG018","value":"0"},{"groupId":"BG019","value":"2"},{"groupId":"BG020","value":"17"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"}],"populationDescription":"The full analysis set included all participants who received at least 1 dose of enapotamab vedotin. Participants were analyzed according to the assigned treatment/dose (planned dose level and schedule)."}